IMA203 + IMA203CD8

IMA203 + IMA203CD8 is a combination of two autologous T cell receptor engineered T cell therapies targeting the cancer-testis antigen PRAME presented on HLA-A*02:01 in patients with advanced solid tumors. IMA203 consists of autologous T cells transduced with a high-affinity PRAME-specific TCR, while IMA203CD8 is a next-generation product co-transduced with the same PRAME TCR and CD8αβ to provide CD4+ T cells with MHC class I–restricted cytotoxic function and to enhance CD8+ T-cell activity, aiming for stronger, more durable anti-tumor responses.[1][2] Both products are developed within Immatics’ ACTengine platform, are being evaluated as monotherapy and in combination with the PD-1 inhibitor nivolumab for recurrent/refractory solid cancers including melanoma, and are administered after lymphodepleting chemotherapy with cyclophosphamide and fludarabine.[1][3][4][5]

Other names

ACTengine IMA203ACTengine IMA203CD8